A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs INCMGA 0012 (Primary) ; MGC-018 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 25 Jan 2019 According to a MacroGenics media release, enrollment of the first dose escalation cohort has been completed.
- 25 Jan 2019 Status changed from not yet recruiting to recruiting, according to a MacroGenics media release.
- 09 Nov 2018 New trial record